Conference Day One
7:30 Check-In & Coffee
8:30 Chair’s Opening Remarks
8:40 Fireside Chat: Reflecting on Lessons Learned from PhII/III Failures to Drive Urgency for Novel CNS Biomarker Research
Synopsis
- Evaluating past failures to identify key missteps, avoid repeating errors, and foster collective learning that propels the field forward with greater cohesion
- The blood-based biomarker revolution: Reviewing the latest progress to increase accessibility, sensitivity and scalability
- Evaluating the latest progress in neuroimaging technologies: Enhancing clinical value, navigating constraints, and integrating with fluid-based approaches
9:30 Driving Precision Medicine in Neurology Through Biomarker-Driven Development
Synopsis
- Exploring biomarker strategies across neurodegenerative therapeutic programs, including Alzheimer’s and rare diseases
- Insights into the application of targeted antibody therapies in advancing clinical development strategies
10:00 Morning Break & Speed Networking
Synopsis
As this community unites, this session will provide valuable networking time with your peers, enabling you to forge new and lasting connections.
Tackling Sample Acquisition & Quality for Highly Precise & Improved Assay Validation
11:00 Optimizing Sample Quality for Improved Clinical Biomarker Reliability, Reproducibility & Data Integrity
Synopsis
- Addressing poorly characterized commercial samples; lack of clinical metadata and Biobank limitations (low volume, poor metadata, inconsistent storage)
- Ensuring the stability of proteins, nucleic acids, and other key analytes during storage and handling in clinical workflows
- Addressing the antibody issue: variability in commercial reagents with unverified clones and poor specificity impacting clinical assay performance
11:30 Panel Discussion: Exploring Sensitivity, Specificity, Credibility & Efficiency of Different Biomarker Detection Platforms for Technological Calibration
Synopsis
- Assessing the sensitivity levels of different techniques for biomarker measurement, such as aptamer-based proteomics assays, liquid chromatography–mass spectrometry and enzyme-linked immunosorbent assay (ELISA)
- Exploring how individual biomarkers are suited to different measurement approaches
12:15 Lunch Break & Networking
Mapping Out the Future of Biomarkers: Emerging Trends & Strategies for Next-Gen Neuroscience Research
1:30 NExT – Neuro Expert Toolbox
Synopsis
- Introduction to Fujirebio Neuro Centre of Excellence – a collaborative environment which welcomes input from experts and partners around the world
- Learn about NExT – toolbox enables partners and customers to access Fujirebio’s expertise at every stage of biomarker development
- From pioneering work in Alzheimer’s diagnostics to a broader vision across the full spectrum of neurological conditions
2:00 Roundtable Discussion: Breakthrough Biomarkers on the Horizon to Stay Ahead of the Curve in Diagnostics & Therapeutics
Synopsis
Join leaders from across academia, industry, and tech to explore the most promising novel and emerging biomarkers transforming neuroscience research:
- Circular RNA: Potential roles in neurodegenerative disease pathogenesis and detection
- Cryptic protein markers: Uncovering hidden drivers of disease and therapeutic response
- Exosome-derived biomarkers: Tapping into extracellular vesicles for CNS signal access
- Immune cell biomarkers: Peripheral immune signatures reflecting neuroinflammatory processes
- Intracellular biomarkers: Tracking cellular-level changes linked to disease progression
- Preventative vaccines approach for neurodegenerative approaches
2:45 NULISA Neurology Biomarker Platform – Brain-derived pTau217 and High-plex Neurodegenerative Disease and Neuroinflammatory Biomarker Analysis
Synopsis
- NULISA™: Ultra-sensitive femtogram level detection with barcode-based high-plex biomarker analysis
- First brain-derived (BD) pTau217 assay for highest accuracy blood-based Alzheimer's detection
- CNS Disease Panel: Unique in its coverage of hundreds of proteins involved in neurodegeneration, inflammation, vascular and synaptic dysfunction. New BD-Tau181,217, 231, total assays
- Inflammation Panel: Comprehensive coverage of cytokines and key immune markers underlying neuroinflammatory disease
- NULISA platform: Unmatched ability to translate targeted neuroimmune proteomic discoveries into low-plex quantitative assays on the same ARGO HT System
- ARGO HT System: Fully automated instrument for running single-, low-, and high-plex assays
- NULISA IVD and ARGO DX in development with funding from Gates Ventures and DxA
3:15 Afternoon Break & Networking
Unified Effort: Collaboration From Academia to Industry & Everything in Between to Identify a Common Goal & Accelerate Biomarker Innovation
4:00 Bridging the Disconnection Between Academia & Clinical Reality to Bridge Translational Gaps & Create a United Language
Synopsis
- How to optimize researchers’ data for seamless clinical translation
- Aligning priorities: Discovery science vs commercial deliverables
4:30 CNS Biomarker Innovation: What Does it Mean for the Patient?
Synopsis
- Highlighting the importance of advanced diagnostic tools for patient enrolment
- Reviewing clinical experience to optimize clinical recruitment and retention
- From invasive diagnostic procedures to novel omics technologies highlighting what’s truly most important for the patient